Lineage Cell Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -46.6% | -46.6% | -24.6% |
| FY2022 | -35.8% | -35.8% | -21.2% |
| FY2023 | -33.9% | -33.9% | -21.3% |
| FY2024 | -23.7% | -23.7% | -16.4% |
| FY2025 | -142.6% | -142.6% | -56.4% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -46.6% | -46.6% | -24.6% |
| FY2022 | -35.8% | -35.8% | -21.2% |
| FY2023 | -33.9% | -33.9% | -21.3% |
| FY2024 | -23.7% | -23.7% | -16.4% |
| FY2025 | -142.6% | -142.6% | -56.4% |